Mispro Expands State-of-the-Art Facilities in Cambridge with New Alewife Location
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Mispro Biotech Services, North America’s leading contract vivarium organization (CVO) with locations in all major U.S. biotech hubs, including a facility in Kendall Square, has announced the addition of a second facility in Cambridge, set to open in Alewife this fall.
Mispro’s Alewife facility will be located in the CambridgePark Drive life sciences park and will offer shared, semi-private, and private options for research space, as well as a low-barrier-to-entry pricing structure that was designed to enable the area’s influx of early-stage companies to launch their in vivo program in a world-class research facility and with minimal budget.
“When looking at expansion in the Cambridge area, it was important for us to find a location where we could best serve early-stage biotechs, which means easy for them to access and friendly to their budget,” said Mispro CEO, Philippe Lamarre. “The CambridgePark campus and the emerging Alewife sub-cluster is bustling with life sciences start-ups and is easily accessible from the Red Line. We’ll also be offering a groundbreaking pricing structure for this location that will enable small companies to launch their in vivo programs with limited funding, or even a credit card.”
In addition to fully equipped research space, Mispro’s contract vivarium (CV) research environments include comprehensive services that are required for preclinical in vivo studies, including husbandry, technical support, and regulatory compliance oversight.
“Mispro has long been the leader in the contract vivarium market in Cambridge and the opening of this facility serves to further strengthen its ability to support early-stage startups as they accelerate preclinical development,” said Kendalle Burlin O’Connell, President and COO, MassBio. “These early-stage companies make up the backbone of the life sciences cluster in Massachusetts and are making big bets on next-generation science that ultimately improves patient lives. We look forward to working with Mispro to ensure these services reach the emerging companies that need them the most.”
Mispro’s expansion to Alewife answers to increased demand in the market for the CV offer, as well as the Alewife location emerging as Cambridge’s most desired biotech address outside of Kendall Square.
“Mispro has been a trusted partner of LabCentral and BioLabs for several years, with many of our resident companies having successfully launched and scaled their in vivo programs in Mispro’s network of facilities. With the opening of BioLabs’ Eisai Innovation Center also in Alewife, we look forward to working closely with Mispro to support preclinical development in Cambridge’s newest emerging sub-cluster,” said Johannes Fruehauf, Founder & CEO LabCentral/BioLabs.
“One thing we’ve certainly learned from our tenure in Cambridge is that, while our clients might come to Mispro for the location and affordability, they’ll stay for Mispro’s commitment to providing world-class research environments and rigorous compliance oversight that results in success for their studies and program. We’re extremely excited about our next chapter in Alewife and doing our part to help the area continue to grow,” said Lamarre.
Mispro plans to open its Alewife facility in the Fall of 2021.
Mispro Biotech Services is a contract vivarium organization (CVO) that operates a network of full-service coworking vivarium facilities where emerging and established biopharma companies can conduct and control their own in vivo studies. Along with offering access to state-of-the-art vivarium research space, Mispro supports its clients with comprehensive animal care and regulatory compliance oversight services. Mispro has locations in all major U.S. and Canadian biotech hubs, including in Cambridge, MA, where they have locations in Kendall Square and, opening Fall 2021, Alewife.
To schedule a tour at any of Mispro’s locations, visit Schedule a Tour.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005310/en/
For media inquiries please contact John Fogarty at email@example.com
Source: Mispro Biotech Services
View this news release online at: